Literature DB >> 8683209

Full protection against African horsesickness (AHS) in horses induced by baculovirus-derived AHS virus serotype 4 VP2, VP5 and VP7.

J L Martínez-Torrecuadrada1, M Díaz-Laviada, P Roy, C Sánchez, C Vela, J M Sánchez-Vizcaíno, J I Casal.   

Abstract

African horsesickness virus serotype 4 (AHSV-4) outer capsid protein VP2, or VP2 and VP5 plus inner capsid protein VP7, derived from single or dual recombinant baculovirus expression vectors were used in different combinations to immunize horses. When the proteins were purified by affinity chromatography, the combination of all three proteins induced low levels of neutralizing antibodies and conferred protection against virulent virus challenge. However, purified VP2 or VP2 and VP5 in the absence of VP7 failed to induce neutralizing antibodies and protection. Immunization with non-purified proteins enhanced the titres of neutralizing antibodies. Again, the combination of the three proteins was able to confer total protection to immunized horses, which showed absence of viraemia. The antigenicity of recombinant VP2 was analysed with a collection of 30 MAbs. Both purified and unpurified recombinant VP2 proteins showed different antigenic patterns in comparison to that of VP2 on virions. An immunization experiment with four more horses confirmed these results. The vaccine described here would not only prevent the disease, but would drastically reduce the propagation of the virus by vectors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8683209     DOI: 10.1099/0022-1317-77-6-1211

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  13 in total

1.  Expression of major piroplasm protein (p33) of Theileria sergenti (Korean isolate) and its immunogenicity in guinea pigs.

Authors:  S W Kang; C H Kweon; E J Choi; Y D Yoon
Journal:  Korean J Parasitol       Date:  1999-12       Impact factor: 1.341

2.  Purification, stability, and immunogenicity analyses of five bluetongue virus proteins for use in development of a subunit vaccine that allows differentiation of infected from vaccinated animals.

Authors:  Jenna Anderson; Emmanuel Bréard; Karin Lövgren Bengtsson; Kjell-Olov Grönvik; Stéphan Zientara; Jean-Francois Valarcher; Sara Hägglund
Journal:  Clin Vaccine Immunol       Date:  2014-01-22

3.  Serologic markers in early stages of African horse sickness virus infection.

Authors:  J L Martínez-Torrecuadrada; M Díaz-Laviada; P Roy; C Sánchez; C Vela; J M Sánchez-Vizcaíno; J I Casal
Journal:  J Clin Microbiol       Date:  1997-02       Impact factor: 5.948

4.  A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse model.

Authors:  Javier Castillo-Olivares; Eva Calvo-Pinilla; Isabel Casanova; Katarzyna Bachanek-Bankowska; Rachael Chiam; Sushila Maan; Jose Maria Nieto; Javier Ortego; Peter Paul Clement Mertens
Journal:  PLoS One       Date:  2011-01-26       Impact factor: 3.240

5.  B-cell epitopes of African horse sickness virus serotype 4 recognised by immune horse sera.

Authors:  Evans M Mathebula; Frederika E Faber; Wouter Van Wyngaardt; Antoinette Van Schalkwyk; Alri Pretorius; Jeanni Fehrsen
Journal:  Onderstepoort J Vet Res       Date:  2017-02-24       Impact factor: 1.792

Review 6.  African Horse Sickness: A Review of Current Understanding and Vaccine Development.

Authors:  Susan J Dennis; Ann E Meyers; Inga I Hitzeroth; Edward P Rybicki
Journal:  Viruses       Date:  2019-09-11       Impact factor: 5.048

7.  Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA).

Authors:  Rachael Chiam; Emma Sharp; Sushila Maan; Shujing Rao; Peter Mertens; Barbara Blacklaws; Nick Davis-Poynter; James Wood; Javier Castillo-Olivares
Journal:  PLoS One       Date:  2009-06-22       Impact factor: 3.240

8.  Ns1 is a key protein in the vaccine composition to protect Ifnar(-/-) mice against infection with multiple serotypes of African horse sickness virus.

Authors:  Francisco de la Poza; Eva Calvo-Pinilla; Elena López-Gil; Alejandro Marín-López; Francisco Mateos; Javier Castillo-Olivares; Gema Lorenzo; Javier Ortego
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

9.  Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge.

Authors:  Berta Alberca; Katarzyna Bachanek-Bankowska; Marta Cabana; Eva Calvo-Pinilla; Elisenda Viaplana; Lorraine Frost; Simon Gubbins; Alicia Urniza; Peter Mertens; Javier Castillo-Olivares
Journal:  Vaccine       Date:  2014-05-14       Impact factor: 3.641

10.  Plant-produced chimeric virus-like particles - a new generation vaccine against African horse sickness.

Authors:  Daria A Rutkowska; Nobalanda B Mokoena; Tsepo L Tsekoa; Vusi S Dibakwane; Martha M O'Kennedy
Journal:  BMC Vet Res       Date:  2019-12-03       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.